Variability of skin Autofluorescence measurement over 6 and 12 weeks and the influence of Benfotiamine treatment

Diabetes Technology and Therapeutics

Volumn 15, Issue 9, 2013, Pages 733-737

  Stirban, Alin ^a   Pop, Alexandra ^a   Fischer, Annelie ^b   Heckermann, Sascha ^b   Tschoepe, Diethelm ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BENFOTIAMINE; PLACEBO; BENPHOTHIAMINE; CHELATING AGENT; THIAMINE;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SKIN; SKIN AUTOFLUORESCENCE MEASUREMENT; TEST MEAL; ANALOGS AND DERIVATIVES; BLOOD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FLUORESCENCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTPRANDIAL STATE; REPRODUCIBILITY;

ADULT; AGED; CHELATING AGENTS; CROSS-OVER STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; REPRODUCIBILITY OF RESULTS; SKIN; THIAMINE;

EID: 84882997370     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0103     Document Type: Article

References (33)

1. Peppa M, Uribarri J, Vlassara H: Advanced glycoxidation. A new risk factor for cardiovascular disease? Cardiovasc Toxicol 2002;2:275-287.
2. Ahmed N, Thornalley PJ: Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-245.
3. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD: Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011;34:442-447.
4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
5. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS: Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25:1055-1059.
6. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
7. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R, Yong A, Striker GE, Vlassara H: Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010;110:911-916.
8. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002;99: 15596-15601.
9. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003;14:728-731.
10. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, Vassalotti JA, Vlassara H: Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003;42:532-538.
11. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ: Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
12. Smit AJ, Gerrits EG: Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:527-533.
13. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-2659.
14. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW: Tissue-Advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 2010;5:51-55.
15. Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, Lutgers HL, Smit AJ, Zeebregts CJ: Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging 2012;28:431-438.
16. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009;52:789-797.
17. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ: Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005;48:1637-1644.
18. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN: Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007;30:1120-1124.
19. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31: 517-521.
20. Stirban S, Nandrean S, Negrean M, Koschinsky T, Tschoepe D: Skin autofluorescence increases postprandially in human subjects. Diabetes Technol Ther 2008;10:200-205.
21. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9: 294-299.
22. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M: Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006;281:9307-9313.
23. Schmid U, Stopper H, Heidland A, Schupp N: Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008;24: 371-377.
24. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG: Benfotiamine in Diabetic Polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600-605.
25. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29:2064-2071.
26. Stirban A, Pop A, Tschoepe D: A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in type 2 diabetes. Diabet Med 2013; doi: 10.1111/dme.12240 [Epub ahead of print]
27. Na R, Stender IM, Ma L, Wulf HC: Autofluorescence spectrum of skin: component bands and body site variations. Skin Res Technol 2000;6:112-117.
28. Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJ: Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012;7:e40427.
29. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, Geyer J, Kopcke W, Sauerland C, Bretzel RG, Federlin KF: Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001;109:330-336.
30. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ: Skin autofluorescence and glycemic variability. Diabetes Technol Ther 2010;12:581-585.
31. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H: Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004;104:1287-1291.
32. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Effects of low- and high-Advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007;85:1236-1243.
33. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS: a-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001;24:726-732.